15 March 2025 : Clinical Research
Evaluating Cardiovascular Risk Factors Among Healthcare Professionals in Iran
Maryam Moshkani Farahani ADE 1, Seyyed Mohammad Saeed Ghiasi BE 1, Maziar Karamali DE 2, Reza Golchin Vafa ABCE 3*DOI: 10.12659/MSM.947409
Med Sci Monit 2025; 31:e947409
Table 3 Concordance analysis of cardiovascular risk assessment tools.
| Agreement | Linear weighted kappa | 95% Confidence interval | P value | Kappa rating |
|---|---|---|---|---|
| ASCVD vs SCORE2 (low risk) | 0.02, 0.44 | Fair | ||
| ASCVD vs SCORE2 (moderate risk) | 0.29, 0.59 | Moderate | ||
| ASCVD vs SCORE2 (high risk) | 0.29, 0.61 | Moderate | ||
| ASCVD vs SCORE2 (very high risk) | 0.06 | 0.03, 0.09 | None to slight | |
| FRS vs SCORE2 (low risk) | 0.152 | −0.06, 0.36 | Slight | |
| FRS vs SCORE2 (moderate risk) | 0.19 | 0.04, 0.33 | Slight | |
| FRS vs SCORE2 (high risk) | 0.185 | 0.04, 0.32 | Slight | |
| FRS vs SCORE2 (very high risk) | 0.018 | 0.001, 0.03 | 0.155 | None |
| FRS vs ASCVD | 0.17, 0.69 | Moderate | ||
| FRS – Framingham Risk Score, SCORE2 – Systematic Coronary Risk Evaluation 2, ASCVD – Atherosclerotic Cardiovascular Disease. | ||||